---
figid: PMC8196589__cancers-13-02506-g001
figtitle: 'Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?'
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8196589
filename: cancers-13-02506-g001.jpg
figlink: /pmc/articles/PMC8196589/figure/cancers-13-02506-f001/
number: F1
caption: 'Schematic overview of the non-present canonical ER/PR pathways (indicated
  by the red crosses) and potential alternative pathways for estrogen and progestogen
  action in TNBC. Normal pointed arrows indicate stimulation, stunted arrows indicate
  inhibition (dashed arrow = weak or uncertain effect). Red crosses indicate the absence
  of the traditional hormonal pathway in TNBC. Inhibitory effect on (mutant)TP53 is
  most likely ERβ specific. (a) Stimulation of hormonal pathways in a physiological
  premenopausal state. (b) Inhibition of hormonal pathways in a physiological postmenopausal
  state. Abbreviations: HRT, hormone replacement therapy; ER, estrogen receptor; PR,
  progesterone receptor; AR, androgen receptor; E2, 17β-estradiol; P4, progesterone;
  DHT/T, dihydrotestosterone and/or testosterone; DHEA, dehydroepiandrosterone; ERE,
  estrogen response element; ARE, androgen response element; TNBC, triple-negative
  breast cancer; RANK, Receptor Activator of Nuclear Factor Kappa-B; RANKL, RANK-ligand;
  NF-κB, nuclear factor kappa-B; GPER, G protein-coupled estrogen receptor; EGFR,
  epithelial growth factor receptor; Src, SRC proto-oncogene, non-receptor tyrosine
  kinase; EGF, epithelial growth factor; Ras, Ras subfamily of small GTPases; Raf1,
  Raf-1 proto-oncogene, serine/threonine kinase; MEK1/2, mitogen-activated protein
  kinase kinase (MAPKK) 1, 2; ERK1/2, mitogen-activated protein kinase (MAPK) 1, 2;
  3β-HSD, 3β-hydroxysteroid dehydrogenase; 17β-HSD, 17β-hydroxysteroid dehydrogenase;
  5α-red, 5α-reductase; (m)TP53, (mutant)tumor protein 53.'
papertitle: 'Estrogens and Progestogens in Triple Negative Breast Cancer: Do They
  Harm?.'
reftext: Mark van Barele, et al. Cancers (Basel). 2021 Jun;13(11):2506.
year: '2021'
doi: 10.3390/cancers13112506
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: triple-negative | hormone-receptor negative breast cancer | ERβ | RANK/RANKL
  | GPER | AR | estrogens | progestogens
automl_pathway: 0.7994014
figid_alias: PMC8196589__F1
figtype: Figure
redirect_from: /figures/PMC8196589__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8196589__cancers-13-02506-g001.html
  '@type': Dataset
  description: 'Schematic overview of the non-present canonical ER/PR pathways (indicated
    by the red crosses) and potential alternative pathways for estrogen and progestogen
    action in TNBC. Normal pointed arrows indicate stimulation, stunted arrows indicate
    inhibition (dashed arrow = weak or uncertain effect). Red crosses indicate the
    absence of the traditional hormonal pathway in TNBC. Inhibitory effect on (mutant)TP53
    is most likely ERβ specific. (a) Stimulation of hormonal pathways in a physiological
    premenopausal state. (b) Inhibition of hormonal pathways in a physiological postmenopausal
    state. Abbreviations: HRT, hormone replacement therapy; ER, estrogen receptor;
    PR, progesterone receptor; AR, androgen receptor; E2, 17β-estradiol; P4, progesterone;
    DHT/T, dihydrotestosterone and/or testosterone; DHEA, dehydroepiandrosterone;
    ERE, estrogen response element; ARE, androgen response element; TNBC, triple-negative
    breast cancer; RANK, Receptor Activator of Nuclear Factor Kappa-B; RANKL, RANK-ligand;
    NF-κB, nuclear factor kappa-B; GPER, G protein-coupled estrogen receptor; EGFR,
    epithelial growth factor receptor; Src, SRC proto-oncogene, non-receptor tyrosine
    kinase; EGF, epithelial growth factor; Ras, Ras subfamily of small GTPases; Raf1,
    Raf-1 proto-oncogene, serine/threonine kinase; MEK1/2, mitogen-activated protein
    kinase kinase (MAPKK) 1, 2; ERK1/2, mitogen-activated protein kinase (MAPK) 1,
    2; 3β-HSD, 3β-hydroxysteroid dehydrogenase; 17β-HSD, 17β-hydroxysteroid dehydrogenase;
    5α-red, 5α-reductase; (m)TP53, (mutant)tumor protein 53.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ESR2
  - AR
  - EGFR
  - GPER1
  - ESR1
  - ERAL1
  - TNFRSF11A
  - MAPK3
  - MAPK1
  - MAP2K1
  - MAP2K2
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - SRC
  - FGR
  - FYN
  - YES1
  - RNASE13
  - HSD3B1
  - pr
  - ar
  - Egfr
  - era
  - puc
  - rl
  - sic
  - Dsor1
  - bnl
  - Src42A
  - Csk
  - Src64B
---
